5-Amino-1MQ COA and Identity Checklist for Canadian Research Labs

Quick answer: what should be on a 5-Amino-1MQ COA?#

A practical 5-Amino-1MQ COA checklist asks whether a Canadian research file can prove what the material is, which lot it came from, how it was tested, how it should be stored, and what compliance boundary the supplier claims. The minimum useful package includes:

1. exact name: 5-Amino-1MQ, preferably expanded as 5-amino-1-methylquinolinium;
2. salt form or counter-ion context where the supplier provides it, such as chloride, bromide, iodide, or another stated form;
3. lot or batch number that connects the vial, product page, COA, invoice, and any supplier correspondence;
4. HPLC or UPLC purity with method context, chromatogram, peak integration, and date;
5. identity confirmation by LC-MS, MS, NMR, or an equivalent analytical method;
6. molecular-weight or molecular-ion information consistent with the declared form;
7. fill amount, net content, container size, and whether the amount is stated as salt mass or free-base equivalent;
8. residual-solvent, reagent, or impurity context where synthesis or quaternization chemistry makes it relevant;
9. COA date, test date, controlled-document marker, lab identity, signature, or other traceability marker;
10. storage instructions for unopened material and any supplier-stated light, moisture, or temperature cautions;
11. research-use-only language without human dosing, route instructions, obesity-treatment claims, testimonials, or performance claims.

That list is different from a standard peptide COA checklist because 5-Amino-1MQ is not a peptide. It is a small-molecule quinolinium compound discussed in NNMT, NAD+ salvage, adipose biology, and one-carbon metabolism research. The 5-Amino-1MQ Canada guide covers mechanism and preclinical context. The where to buy 5-Amino-1MQ in Canada checklist covers supplier selection. This page is narrower: what should the batch record show before a lab accepts a specific lot into a research file?

This article stays inside research-use-only boundaries. It does not provide human dosing, route guidance, treatment advice, obesity-management advice, bodybuilding guidance, personal-use recommendations, or claims that any supplier lot is safe or effective for humans.

Why 5-Amino-1MQ needs a compound-specific identity checklist#

Generic COA review is useful, but 5-Amino-1MQ has several details that deserve a dedicated checklist.

First, the compound is often sold in peptide catalogues even though it is not a peptide. That creates an easy language error: calling it a peptide can lead reviewers to focus on sequence, lyophilized peptide handling, and reconstitution assumptions while missing the small-molecule controls that actually matter. The material should be reviewed as 5-amino-1-methylquinolinium, an NNMT inhibitor, not as a generic metabolic peptide.

Second, exact identity matters because similar-looking quinolinium names are not interchangeable. A product page that says only “1MQ,” “quinolinium compound,” or “NNMT inhibitor” is weaker than one that names 5-amino-1-methylquinolinium. The 5-amino position is part of the identity. Positional isomers, alternate substitutions, different counter-ions, or unrelated quinolinium salts can create a mismatch between the research question and the supplied material.

Third, salt form can change practical interpretation. A COA may report mass or purity against a salt form rather than the free cation. If a supplier says “50 mg” without clarifying whether that refers to salt mass or free-base equivalent, a methods reviewer may not be able to reconstruct the actual material basis later. The goal is not to turn every procurement note into a medicinal-chemistry dossier. The goal is to remove avoidable ambiguity from the batch file.

Fourth, the supplier claim environment matters. 5-Amino-1MQ is searched by people interested in body-composition and weight-management outcomes, but Northern Compound treats it as RUO research material. A credible supplier page should not borrow from wellness marketing, human transformation copy, injection protocols, cycle language, or obesity-treatment claims. The more a page sounds like a consumer-use protocol, the less useful it becomes as a compliant research record.

One-page 5-Amino-1MQ COA checklist#

Use this table as a compact worksheet for procurement notes, supplier audits, or batch documentation.

The table is intentionally practical. It does not require every small supplier to publish a full regulatory dossier. It does require the buyer to document what was visible, what was missing, what was requested, what was received, and why the final decision was made.

Identity layer: name, isomer, and counter-ion#

The first review layer is identity. 5-Amino-1MQ should not be accepted into a research file on the basis of a broad category label. The file should show that the material is the intended quinolinium compound.

A strong record gives the exact name and, ideally, the expanded chemical name. It may also include a CAS number, molecular formula, molecular weight, or molecular-ion information. Those details should not conflict across the product page, COA, label, and supplier response. If the product page says 5-Amino-1MQ but the COA says a different quinolinium material, the file needs clarification before the lot is released for use.

Salt form is the next identity issue. Many charged small molecules are supplied as salts. For 5-Amino-1MQ, the buyer should capture whether the material is presented as a chloride, bromide, iodide, or another form, or whether the supplier does not state the form. A missing salt statement is not always an automatic reject, but it should be recorded as a limitation because it affects molecular-weight interpretation, comparison between suppliers, and long-term method reproducibility.

This is especially important when the research record later compares multiple lots. A lab that changes supplier or salt form without noting it may create an uncontrolled variable. If a model changes response, the problem may be biology, handling, analytical method, counter-ion, impurity profile, or simple documentation drift. The checklist exists to reduce that ambiguity.

Purity layer: HPLC is useful, but not enough by itself#

HPLC or UPLC purity is one of the most visible parts of a COA. It is also one of the easiest fields to over-read.

A chromatogram can show that a tested sample has a major peak under a specific method. It does not automatically prove that the peak is 5-Amino-1MQ. It does not prove the salt form. It does not prove the lot was stored correctly after testing. It does not prove sterility. It does not prove biological activity. It does not prove legality or suitability for human use.

For 5-Amino-1MQ, purity evidence is strongest when paired with identity evidence. A useful package may include HPLC or UPLC purity plus LC-MS, MS, NMR, or another identity method. If the supplier publishes a chromatogram, the reviewer should capture the method name, detection wavelength if shown, retention time, integration percentage, test date, and whether the lot number matches the current vial. If the supplier only shows “99% purity” in marketing copy, the number should be treated as a claim until a lot-matched COA supports it.

Method context also matters because quinolinium compounds can behave differently from neutral peptides under chromatography. Ionic character, counter-ion, ion-pairing reagents, mobile phase, detection wavelength, and sample preparation can all affect the trace. A Canadian lab does not need to validate the supplier’s method from scratch for every procurement decision, but it should know whether the purity claim is attached to a real method or a decorative badge.

Use the broader peptide COA verification checklist for universal document review. Use this 5-Amino-1MQ checklist for the compound-specific identity and small-molecule details that a peptide-first checklist can miss.

Lot traceability: the batch file should survive an audit#

A COA is only useful if it can be tied to the material in hand.

At minimum, the batch file should connect five records: product page, vial label, COA, invoice or order record, and receiving note. If the lot number appears on only one of those records, the reviewer should record the gap. If the lot number differs across records, the lot should be quarantined until the supplier explains the mapping. If the supplier provides a support email saying that two codes refer to the same lot, save the email with the batch file rather than relying on memory.

Good traceability also captures timing. Product pages change. COAs get replaced. Supplier catalogues may update claims, storage language, or document links. A useful research file should archive the product page or at least save the access date, product URL, COA date, and retrieval date. That creates a stable record of what the lab relied on at the time of purchase.

For 5-Amino-1MQ, traceability is especially useful because the compound sits at the edge of several search-intent buckets: metabolic research, NNMT inhibition, NAD+ salvage, adipose biology, and weight-management-adjacent queries. The supplier page may emphasize one bucket more than another. The batch file should preserve the actual language so later reviewers can judge whether the original sourcing decision was appropriately framed.

Residual-solvent and impurity questions for a small-molecule NNMT inhibitor#

Peptide COAs often focus on sequence, mass, HPLC purity, water content, and sometimes acetate or trifluoroacetate context. A small molecule such as 5-Amino-1MQ raises additional questions.

The reviewer should ask whether the supplier provides any residual-solvent, reagent, or impurity context. Depending on the synthesis route, quinolinium materials can involve methylation, quaternization, purification, counter-ion exchange, crystallization, or salt formation. The lab does not need the supplier’s proprietary route to make a basic procurement decision. But if the material will be used in sensitive cellular, metabolic, or analytical assays, unexplained residuals can matter.

The practical question is simple: could an impurity plausibly affect the endpoint? For an NNMT model, a contaminant that affects cell viability, mitochondrial respiration, methylation balance, or fluorescence detection could distort interpretation. For an LC-MS method-development project, an impurity or counter-ion mismatch could complicate calibration and peak assignment. For a storage study, residual moisture or solvent could affect stability.

If the COA does not include residual-solvent or impurity data, record that limitation. If the supplier can provide it, attach it. If the project is exploratory and low sensitivity, the limitation may be acceptable. If the project depends on precise metabolic readouts, the limitation may justify a clarification request, a different lot, or a different supplier.

Storage and receiving: capture the boring details before they become expensive#

Storage language is often treated as boilerplate. It should not be.

For 5-Amino-1MQ, the receiving file should capture the supplier’s stated storage condition, whether the material should be protected from light or moisture, whether the container arrived sealed, whether the label matches the order, and whether any shipping condition created a concern. A dry small molecule may not require the same cold-chain assumptions as a fragile peptide, but that does not mean storage is irrelevant. Light, moisture, heat, container integrity, and repeated opening can all affect a research file’s confidence.

A simple receiving note is enough for most RUO procurement:

• date and time received;
• supplier and order number;
• product name and lot number;
• container condition;
• label match or mismatch;
• visible damage, leakage, powder appearance, or seal concern;
• supplier storage instruction copied or screenshot with access date;
• accept, accept with limitation, quarantine, or reject decision.

This receiving note should sit beside the research peptide batch documentation template, even though 5-Amino-1MQ is not a peptide. Northern Compound uses the template as a research-material record structure, not as a claim that every listed material is chemically a peptide.

Supplier-claim review: compliance is part of material quality#

A polished COA cannot fully rescue a supplier page that makes poor claims.

For RUO sourcing, the product page should avoid human-use language. Red flags include human dosing tables, injection instructions, obesity-treatment claims, guaranteed fat-loss promises, cycle plans, bodybuilding positioning, before-and-after stories, testimonials, disease-treatment copy, or statements that blur research use with personal experimentation. Those claims do not necessarily prove that the material is analytically wrong, but they weaken the supplier’s compliance posture and create documentation risk.

The cleanest language is boring: research use only, not for human or veterinary use, batch-tested, current lot available, storage conditions stated, and documentation available on request. A page that keeps the claim boundary narrow is easier to file than one that forces the lab to explain why it ignored consumer-use copy.

This is why Northern Compound routes commercial readers through ProductLinks while keeping the article itself cautious. A ProductLink can help a qualified reader inspect a live product page and preserve attribution. It is not a certification, endorsement of a current batch, medical recommendation, or substitute for independent review.

How to score a 5-Amino-1MQ supplier file#

A simple scoring system keeps the decision consistent across suppliers and lots. Use five domains, each scored 0 to 2.

Interpretation:

• 0–3: reject or quarantine until clarified;
• 4–6: usable only with documented limitations and low-risk exploratory context;
• 7–8: acceptable if the project does not require enhanced impurity controls;
• 9–10: strong procurement file for RUO research use.

The score is not a legal conclusion or a safety guarantee. It is a documentation tool. A low score tells the lab where to ask follow-up questions. A high score tells the lab that the file is less likely to waste time during methods review, manuscript preparation, internal QA, or supplier comparison.

Internal-link workflow for Canadian labs#

A complete 5-Amino-1MQ review should not live alone. Use the following Northern Compound pages as a practical chain:

1. Start with the 5-Amino-1MQ Canada guide to confirm that the mechanism and evidence stage fit the research question.
2. Use the where to buy 5-Amino-1MQ Canada checklist when comparing supplier pages.
3. Apply this COA and identity checklist to the specific lot under review.
4. Use the research peptide supplier scorecard to compare vendors across documentation, support quality, and claim discipline.
5. File the result with the batch documentation template and the RUO compliance checklist.

That chain separates mechanism, supplier selection, batch evidence, and compliance. It also prevents the most common mistake in metabolic-product searches: letting the catalogue page define the research question.

Common failure modes#

Treating 5-Amino-1MQ like a peptide#

This is the most common documentation error. 5-Amino-1MQ may be sold beside peptides, but its identity evidence is chemistry-first. Do not ask only for sequence-style peptide information. Ask for exact small-molecule identity, salt form, purity method, and MS/NMR support where available.

Accepting HPLC purity as identity#

A clean HPLC trace is useful. It is not the whole identity package. Without LC-MS, MS, NMR, or another identity method, the record may show that a sample is mostly one component without proving that the component is the intended NNMT inhibitor.

Ignoring salt form#

If one supplier reports free-base equivalent and another reports salt mass, apparent comparisons can become misleading. Capture the salt or counter-ion when available. If it is not available, record the missing field as a limitation.

Filing supplier marketing claims without review#

A product page that includes dosing, injection, “fat loss,” transformation, or personal-use copy should be flagged. The batch file should show that the lab noticed the claim problem and decided whether it affected supplier suitability.

Forgetting the access date#

Product pages and COA links change. Screenshots, PDFs, retrieval dates, and archived notes make the review reproducible. Without them, a later reviewer may not be able to reconstruct what was actually available at purchase.

Supplier clarification email template#

When a 5-Amino-1MQ file is almost usable but missing one or two fields, a short clarification request is better than a vague internal note. The email should ask for specific documents and avoid any language that implies personal use.

Suggested template:

Hello,

We are reviewing the current 5-Amino-1MQ lot for research-use-only documentation. Could you confirm whether the available COA is lot-matched to the product currently shipping and whether the material is supplied as a specific salt or counter-ion form? If available, please also provide identity support beyond HPLC purity, such as LC-MS, MS, NMR, or an equivalent analytical record, plus any residual-solvent or impurity statement relevant to the current lot.

We are not requesting medical, dosing, route, or human-use information. This request is limited to batch identity, purity, traceability, storage, and RUO documentation.

Thank you.

Save the request and the supplier response with the batch file. If the supplier answers only in generalities, record that the answer did not resolve the lot-specific question. If the supplier provides a PDF or screenshot, record the file name, retrieval date, and lot number. If the supplier changes the product page after the request, save the new access date rather than overwriting the old one.

A good response should answer the exact question. “All products are high purity” is not the same as “Lot 5AMQ-2409 was tested by HPLC on this date and identity was confirmed by LC-MS.” “Store in a cool dry place” is not the same as a temperature-defined condition. “We use third-party testing” is not the same as a lot-matched third-party COA. The checklist should separate actual evidence from supportive but non-specific reassurance.

Accept, accept with limitation, quarantine, or reject#

A checklist is only useful if it leads to a decision. The final decision should be one of four options.

Accept means the file supports the exact material, lot, identity, purity, storage, and RUO claim boundary well enough for the planned research context. The reviewer should still record limitations, but no blocking questions remain.

Accept with limitation means the file is usable only because the project does not depend on the missing field. For example, a preliminary supplier-comparison screen may tolerate missing residual-solvent detail if identity, purity, lot matching, and RUO language are strong. A sensitive cellular metabolism assay may not.

Quarantine means the material should not enter the research workflow until a specific question is resolved. Common quarantine triggers include lot mismatch, unclear identity, conflicting salt form, missing COA, damaged container, inconsistent product name, or supplier page language that creates compliance concerns.

Reject means the supplier file is not fit for the intended research purpose. Rejection is appropriate when the supplier cannot connect the COA to the current lot, cannot identify the material beyond a generic name, presents human-use or treatment claims as core product copy, or provides records that conflict in ways the supplier cannot explain.

The important part is not the label itself. It is the reason. A batch file that says “Rejected: COA lot does not match vial lot and supplier could not reconcile the codes” is useful. A batch file that says “Rejected: looks sketchy” is not.

How this differs from GLP-1 and peptide COA review#

5-Amino-1MQ sits in the weight-management archive beside incretin and metabolic research materials, but it should not inherit their documentation assumptions.

For Semaglutide, Tirzepatide, or other peptide-based incretin research materials, the reviewer often asks about peptide sequence, molecular mass, lyophilized fill, acetate or TFA context, cold-chain assumptions, and receptor-specific endpoint fit. The GLP-1 research compound comparison matrix is built around those receptor and stability questions.

For 5-Amino-1MQ, the better starting point is small-molecule analytical identity. The reviewer should ask whether the material is the intended quinolinium compound, whether the salt or counter-ion is stated, whether the purity method is appropriate, whether identity is supported by MS or NMR, and whether residual chemistry could matter for the endpoint. The research question may still be metabolic, but the material file is different.

That difference also affects internal comparisons. A study that compares 5-Amino-1MQ with MOTS-c, AOD-9604, or NAD+ should not use one generic “metabolic peptide quality” standard for every arm. Each material needs a quality file that matches its chemistry and endpoint.

A practical record layout#

For most Canadian RUO labs, a simple folder structure is enough:

5-amino-1mq/
  lot-identifier/
    01-product-page-screenshot.pdf
    02-coa-current-lot.pdf
    03-invoice-or-order-record.pdf
    04-receiving-note.md
    05-supplier-clarification-email.pdf
    06-review-scorecard.md
    07-final-disposition.md

The folder should contain the evidence, not just a summary. If the product page changes, add a new screenshot rather than replacing the old one. If the COA is updated, keep the previous file and note why the new one supersedes it. If a supplier says the same lot has two internal codes, save that explanation. If the final decision changes from quarantine to accept, leave the quarantine note in place and add the reason for release.

This record layout is intentionally lightweight. It does not require a full regulated quality system. It gives a small research team enough structure to avoid re-litigating the same supplier questions every time a vial is received.

References and further reading#

• Neelakantan H. et al. “Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.” Biochemical Pharmacology (2017). PubMed.
• Kannt A. et al. “Nicotinamide N-methyltransferase knockdown in adipocytes increases energy expenditure and improves insulin sensitivity.” Diabetes (2014). PubMed.
• Ulanovskaya O.A. et al. “NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink.” Nature Chemical Biology (2013). PubMed.
• Yoshino J., Baur J.A., Imai S. “NAD+ intermediates: the biology and therapeutic potential of NMN and NR.” Cell Metabolism (2018). PubMed.
• Li J. et al. “NNMT inhibition increases energy expenditure and promotes adipose tissue browning.” Biochimica et Biophysica Acta (2018). PubMed.
• Health Canada. “Drugs and health products compliance and enforcement.” Health Canada.